NCT00462878

Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

MERONEM: Observational Study About Efficacy of Meropenem in Comparison of Meropenem and Glycopeptide in Treatment of Neutropenia Febrile in Allogenic Blood Stem Cell Transplantation Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 392 (estimated)
• Sponsor: PETHEMA Foundation · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Observational study to compare the treatment in neutropenic patients after allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide.

Detailed description

Observational study cost-effectivity to compare the treatment in neutropenic patients after allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide. The study will be done in two consecutive cohorts of patients. First cohort: meropenem 1g/8h ev Second cohort: meropenem 1g/8h and glycopeptide (vancomycin 1g/12 h or teicoplanin 400 mg/24h)

Conditions

• Allogenic Blood Stem Cell Transplantation
• Febrile Neutropenia

Interventions

Type	Name	Description
DRUG	Meropenem	antibiotic
DRUG	Vancomycin	Antibiotic
DRUG	Teicoplanin	Antibiotic

Timeline

• Start date: 2002-11-01
• Completion: 2009-04-01
• First posted: 2007-04-19
• Last updated: 2009-05-12

Locations

64 sites across 1 country: Spain